Bionomics Investor Presentation Deck slide image

Bionomics Investor Presentation Deck

The Mechanism and Pharmacology of BNC210 Demonstrate its Advantages over Current Therapies for Anxiety Disorders and PTSD* SSRIs & SNRIS 1 BZDs ² (Off-label) BNC210 Fast Onset of Action X ✓ ✓ Not Sedating ✓ X ✓ No Withdrawal/ No Memory Abuse Potential Impairment ✓ X X ✓ X ✓ No Motor Impairment ✓ X ✓ * Potential benefits based on analysis of data from separate studies and not on results that might have been obtained from head-to-head studies. Such data may not be directly Bionomics comparable due to differences in study protocols, conditions and patient populations. Accordingly, cross-trial comparisons may not be reliable predictors of the relative efficacy or other benefits of BNC210 compared to existing therapies or other product candidates that may be approved or are in development for the treatment of PTSD or SAD. 1. Includes Valium and certain other benzodiazepines 2. Includes Prozac and certain other SSRIs (Selective Serotonin Reuptake Inhibitors) / SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) No Suicidal Ideation X ✓ ✓ 7 8
View entire presentation